287 related articles for article (PubMed ID: 28413914)
1. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
Umino K; Fujiwara SI; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Lymphoma; 2017 Feb; 58(2):316-323. PubMed ID: 27267694
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
[TBL] [Abstract][Full Text] [Related]
7. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
Tomita N; Sakai R; Fujisawa S; Fujimaki K; Taguchi J; Hashimoto C; Ogawa K; Yamazaki E; Ishigatsubo Y
Cancer Sci; 2012 Aug; 103(8):1518-23. PubMed ID: 22587388
[TBL] [Abstract][Full Text] [Related]
8. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.
Yoshizato T; Nannya Y; Imai Y; Ichikawa M; Kurokawa M
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):410-6. PubMed ID: 23747081
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma.
Nozaki K; Sugahara H; Ueda S; Ishikawa J; Fuji S; Masaie H; Tada Y; Karasuno T; Iida M; Mitsui H; Kamae T; Saito N; Moriyama Y; Kawakami M; Kato R; Nakae Y; Kida T; Kosugi S; Nakagawa M; Uchida Y; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
Leuk Lymphoma; 2020 Sep; 61(9):2113-2121. PubMed ID: 32366194
[TBL] [Abstract][Full Text] [Related]
12. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
Clin Cancer Res; 2013 Dec; 19(23):6624-32. PubMed ID: 24130072
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
[TBL] [Abstract][Full Text] [Related]
16. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy.
Kusano Y; Yokoyama M; Terui Y; Inoue N; Takahashi A; Yamauchi H; Tsuyama N; Nishimura N; Mishima Y; Takeuchi K; Hatake K
Blood Cancer J; 2017 Sep; 7(9):e614. PubMed ID: 28960192
[No Abstract] [Full Text] [Related]
17. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
18. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
Kelly JL; Salles G; Goldman B; Fisher RI; Brice P; Press O; Casasnovas O; Maloney DG; Soubeyran P; Rimsza L; Haioun C; Xerri L; LeBlanc M; Tilly H; Friedberg JW
J Clin Oncol; 2015 May; 33(13):1482-90. PubMed ID: 25823738
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
20. [Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma].
Oliver C; Guillermo C; Martínez P; Díaz L
Rev Med Chil; 2013 Jul; 141(7):844-52. PubMed ID: 24356732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
